Navigation Links
Acne Cream Not Linked to Raised Death Risk
Date:1/23/2009

Analysis of VA study that was halted early says retinoid tretinoin not the culprit

FRIDAY, Jan. 23 (HealthDay News) -- A new analysis suggests that an acne medication that was tried as a possible skin cancer preventative in a 1998 clinical trial probably did not cause the deaths of several veterans participating in that research.

The earlier study was halted six months early, when a increased risk of death was seen in those using retinoid tretinoin cream when compared to those taking a placebo.

However, a closer look at the data from that trial did not uncover a definitive link between the treatment and an increased risk of death.

"We didn't see any evidence for a cause-and-effect relationship," said Dr. Martin Weinstock, chief of dermatology at VA Medical Center in Providence, R.I., and a professor of dermatology and community health at Brown University, also in Providence.

Weinstock was lead author of the latest analysis, which was published in the January issue of the Archives of Dermatology and was funded by the U.S. Department of Veterans Affairs.

"This shouldn't change clinical practice, and it's not going to change my clinical practice," added Dr. Jonette Keri, an assistant professor of dermatology and cutaneous surgery at the University of Miami Miller School of Medicine and chief of dermatology at the Miami VA Hospital. "I think it's a very safe medicine with a lot of benefits."

Keri was one of the investigators on the original study, known as the Veterans Affairs Topical Tretinoin Chemoprevention (VATTC). The concept was to investigate whether a cream containing a high dose of retinoid tretinoin could keep certain types of skin cancer, particularly basal and squamous cell malignances, at bay in high-risk people.

"Systemic retinoids are known to be effective in reducing the risk of certain carcinomas in certain high-risk contexts such as renal transplant recipients," Weinstock explained. "The question was, might they be effective in preventing skin cancer not in a super high-risk population but a high-risk population.

The study enrolled 1,131 veterans (average age 71), almost all of them male. Participants were randomly assigned to apply a cream containing 0.1 percent tretinoin (the highest dose commercially available) or a placebo cream to their face and ears twice a day.

Patients with a high risk of death within three years, including prior cancer or other serious medical condition such as advanced heart disease, were excluded from the trial.

The trial was halted in May 2004 due to unexpectedly higher death rates in the treatment arm of the study (82 died in the treatment arm, vs. 53 in the placebo arm).

But the absence of a dose-response relationship, several different causes of death, and minimal absorption of the cream indicated that tretinoin was not responsible for the increased mortality, the authors of the new analysis stated. Also, whether or not the veterans smoked or had smoked was not verified, and retinoids have been associated with an increased risk of death among smokers.

Another thing to consider, the study authors pointed out, is that the trial was done in older people, a group that has not specifically been studied in relation to this issue.

OrthoNeutrogena, the makers of Retin-A, concurred with the findings. "The results of this study did not demonstrate a causal relationship between treatment with Tretinoin and mortality," the company said in a statement. "The study author findings are consistent with OrthoNeutrogena's systematic review of available published literature, which did not find evidence of a relationship between any systemic adverse events and topical Tretinoin."

More information

The U.S. National Library of Medicine has more on tretinoin.



SOURCES: Martin A. Weinstock, M.D., Ph.D., chief, dermatology, VA Medical Center, and professor, dermatology and community health, Brown University, Providence, R.I.; Jonette Keri, M.D., Ph.D., assistant professor, dermatology and cutaneous surgery, University of Miami Miller School of Medicine, and chief, dermatology, Miami VA Hospital; Jan. 23, 2009, statement, OrthoNeutrogena; January 2009, Archives of Dermatology


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. In Time, Cream Might Prevent Herpes Transmission
2. Kroger Recalls Select Ice Cream Products Due to Possible Health Risk
3. FDA Approves Durameds Synthetic Conjugated Estrogens-A Vaginal Cream
4. Wrinkle Cream Reviews Site Reveals a Winner for 2008's Best Wrinkle Creams : Wrinkle Cream reviewssite, WrinkleBest.com has released the Editor's Choice for Best Wrinkle Cream of 2008
5. FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause
6. FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse
7. Happy Birthday, StriVectin! The Skin Cream that Revolutionized the Anti-Aging Market
8. Sun Safety Champions Team Up With LPGA Tour Pro Paula Creamer
9. Tomlinson Attributes Rebound to Anti-Inflammatory Cream
10. Estrogen Cream No Match for Sun-Damaged Skin
11. Clean, Chemical-Free Eye Cream Evening Primrose Oil: The Puffy-Eye Cure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Acne Cream Not Linked to Raised Death Risk
(Date:4/28/2017)... ... April 28, 2017 , ... Children ... to more adverse experiences than children in the general population. That’s because foster ... neglect or other family challenges. While no fault of their own, youth who ...
(Date:4/28/2017)... ... ... People are starting to accept that hearing aids can be helpful and ... it had when great-grandpa wore his hearing aids years ago,” said Dr. Maura Marks, ... American Speaker Series (NASS) segment. “He probably wore an iPod-size hearing aid on ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... Manager for the North East region. Côté has 20+ years of experience within ... to Phytomer, Côté worked with an array of high-end cosmetic brands, retail brands ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Rob Lowe ... and now he has leant his presence to an educational purpose as the host ... one important one being cancer. In a recent episode, the series focuses on thyroid ...
(Date:4/27/2017)... ... April 27, 2017 , ... The Incentive Research Foundation is ... Nudge Guide," a groundbreaking analysis of how behavioral economics can be applied to ... to IRR programs, the report highlights proven behavioral economics approaches and the powerful ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... Research and Markets has announced ... Market Prospects: Addressing Production Complexities Through Risk Management and ... ... Pipeline and Market Prospects: Overcoming Production Complexities Through Risk ... of the current trends in the global biosimilars market, ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
Breaking Medicine Technology: